" class="no-js "lang="en-US"> Harbour BioMed - Medtech Alert
Wednesday, June 19, 2024
Harbour BioMed | Pharmtech Focus

Harbour BioMed

About Harbour BioMed

Harbour BioMed

Harbour BioMed (HKEX: 02142.HK) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Related Story

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

March 6 2023

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel […]

Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

April 14 2022

Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), today announced the appointment of Dr. Humphrey Gardner as Chief […]

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

June 16 2021

Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration […]